Ali H.
- Country
- France
- Department
- Radiology/Oncology
Research Overview
- Phase III Randomized Trial of Docetaxel plus Apalutamide Intensification in Metastatic Hormone-Sensitive Prostate Cancer with Inadequate PSA Response
- Phase 3 Multinational Randomized Study of Sasanlimab with Bacillus Calmette-Guerin in High-Risk Non-Muscle Invasive Bladder Cancer
- Evaluation of Darolutamide Combined with Stereotactic Body Radiation Therapy in Castration-Resistant Prostate Cancer with Oligometastases Detected by Functional Imaging
Data & Insights
Has run more than one trial at 146 of 394 partner sites.
Specializations
Prostate Cancer Treatment
The investigator specializes in managing various stages of prostate adenocarcinoma, with particular emphasis on high-risk localized disease and metastatic conditions.
- Novel Hormone Therapy Applications
- Castration-Resistant Disease Management
- Post-Surgery Treatment Strategies
Areas of focus include the integration of androgen receptor inhibitors and combined therapeutic approaches for advanced disease states.
Advanced Cancer Therapeutics
The investigator conducts research in treating oligometastatic cancer and employs innovative approaches combining radiotherapy with systemic treatments.
- Stereotactic Radiation Therapy
- Hormone-Sensitive Disease Treatment
- Multimodal Treatment Approaches
Expertise extends to managing biochemical recurrence and implementing targeted therapeutic strategies.
Urological Oncology
Research interests include the treatment of non-muscle invasive bladder cancer and various urological malignancies using novel therapeutic combinations.
- Immunotherapy Applications
- Treatment-Resistant Disease
- Head and Neck Cancer Management
Focus areas encompass functional imaging applications and precision medicine approaches in cancer treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.